Drug intelligence / Profile preview

formocortal

Development stage: Discontinued
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Topical, Ophthalmic

Overview

Formocortal is a synthetic corticosteroid with anti-inflammatory properties. It acts as a glucocorticoid receptor agonist and has been used primarily in dermatology and ophthalmology for the treatment of inflammatory conditions. The drug was introduced around 1970 but is not known to be marketed as of recent years. Its mechanism of action involves binding to the glucocorticoid receptor (NR3C1), leading to modulation of gene expression that suppresses inflammation[1][4][5].

Brand names: DeflameneFluderma
Other names: fluoroformylon

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on formocortal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on formocortal.

Explore the full profile